Comparative Pharmacology
Head-to-head clinical analysis: FOLEX versus NIPENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLEX versus NIPENT.
FOLEX vs NIPENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate, the active ingredient in FOLEX, is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with thymidylate and purine synthesis, leading to inhibition of DNA replication and cell proliferation.
Purine nucleoside analog that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting ribonucleotide reductase and DNA polymerases.
30 mg/m2 intravenously once weekly for 2 weeks followed by a 1-week rest period, or 5-10 mg/m2 intramuscularly or intravenously every 3-4 weeks. For rheumatoid arthritis, 7.5-15 mg orally once weekly.
5 mg/m2 intravenously over 20-30 minutes every 3 weeks.
None Documented
None Documented
Terminal half-life: 3-10 hours (mean ~5 hours) for low-dose regimens; higher doses or renal impairment may prolong half-life up to 24 hours.
Terminal elimination half-life is approximately 5-8 hours in patients with normal renal function. Clinically, the half-life may be prolonged in renal impairment, requiring dose adjustments.
Primarily renal excretion of unchanged drug: ~80-90% within 24 hours. Biliary/fecal excretion accounts for <10%.
Primarily renal excretion; approximately 50-70% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination accounts for <5%.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent